Boulogne-billancourt, France
Boulogne-billancourt, France

Ipsen is a French pharmaceutical company headquartered in Paris, France. It primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders. It is publicly traded on the Euronext Paris as part of the SBF 120 index. Wikipedia.


Time filter

Source Type

An aqueous pharmaceutical composition comprising a peptide and one or more water-soluble or water-dispersible gelling agents.


The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.


The present invention relates to a parenteral sustained and controlled release semisolid formulation comprising an oligomer end-capped and an active substance without any supplementary viscosity reducing agent or excipient.


A system and method for facilitating the maintenance of an industrial heat treating furnace are disclosed.


The present invention relates to the use of Lys-C for proteolytically processing a single-chain botulinum neurotoxin serotype B (BoNT/B) or F (BoNT/F) by hydrolysis to produce di-chain botulinum neurotoxin serotype B (BoNT/B) or F (BoNT/F), as well as related methods.


Patent
Ipsen | Date: 2016-10-24

A process for the large-scale synthesis of a therapeutic peptide using solid-phase Fmoc-chemistry.


Patent
Ipsen | Date: 2016-09-30

Pharmaceutical compositions, in particular, compositions comprising growth hormone (GH) and insulin-like growth factor (IGF-1) which are stable at a desirable pH without aggregation formation, and processes for preparing such compositions.


The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.


The invention provides methods for producing soluble di-chain BoNT/A protein.


Patent
Ipsen and Louisiana State University | Date: 2016-08-22

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.

Loading Ipsen collaborators
Loading Ipsen collaborators